What’s the current market cap for Glaukos stock?

Glaukos (GKOS) has a market cap of $7.5bn as of June 18, 2026.

What is the P/E ratio for Glaukos stock?

The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of June 18, 2026.

Does Glaukos stock pay dividends?

No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of June 18, 2026.

When is the next Glaukos dividend payment date?

Glaukos (GKOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Glaukos?

Glaukos (GKOS) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Glaukos stock | $GKOS Share Price

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Ticker

$GKOS

Sector

Health

Primary listing

NYSE

Employees

1,094

Headquarters

Aliso Viejo, United States

Website

www.glaukos.com

Glaukos Metrics

BasicAdvanced

$7.5bn

-

-$3.29

0.95

-

What the Analysts think about Glaukos

Analyst ratings (Buy, Hold, Sell) for Glaukos stock.

Bulls say / Bears say

First-quarter 2026 revenues of $150.6 million climbed 41% year-over-year and beat consensus, reflecting robust adoption of the iStent portfolio (Zacks Equity Research).

In Q4 2025, U.S. glaucoma net sales reached a record $86.4 million, up 53% year-over-year, highlighting accelerating penetration in the largest ophthalmic market (Business Wire).

Commercial launch of Epioxa™ in March 2026 introduced the first FDA-approved topical therapy for keratoconus, expanding Glaukos’s corneal health portfolio into a largely underpenetrated market (Business Wire).

GAAP net loss widened to 34 cents per share in Q1 2026, indicating that the company remains unprofitable despite narrowing adjusted losses (Zacks Equity Research).

Glaucoma treatments accounted for approximately 83% of Q4 2025 net sales, leaving the company heavily exposed to competitive pressures and adoption risks in the MIGS market (Business Wire).

Reaffirmed 2026 net sales guidance of $600 million to $620 million implies year-over-year growth of just 18% to 22%, signifying a potential deceleration from the 32% sales increase achieved in 2025 (Business Wire).

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

Glaukos Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Glaukos Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Glaukos News

AllArticlesVideos

Glaukos Announces Participation in Upcoming Investor Conferences

Business Wire·1 month ago

Glaukos Announces the Release of its 2025 Sustainability Report

Business Wire·2 months ago

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.